|

Maridebart cafraglutide Clinical Trials

3 actively recruiting trials across 3 locations

▲ +1 trial since August 2026

Also known as: AMG 133, MariTide

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Amgen3

Indications

  • Obesity2
  • Overweight or Obesity and Elevated Liver Fat1
  • Heart Failure With Mildly Reduced Ejection Fraction1
  • Liver Disease1
  • Heart Failure With Preserved Ejection Fraction1

Birmingham, Alabama1 trial

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

University of Alabama Saint Vincent's Birmingham

Phase 3

Chandler, Arizona1 trial

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Arizona Clinical Trials

Phase 2

Gilbert, Arizona1 trial

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Gilbert Center for Family Medicine

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.